Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.
Tabei T, Nakaigawa N, Kaneta T, Ikeda I, Kondo K, Makiyama K, Hasumi H, Hayashi N, Kawahara T, Izumi K, Osaka K, Muraoka K, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Kobayashi K, Inoue T, Yao M.
Tabei T, et al.
BMC Cancer. 2019 Apr 2;19(1):298. doi: 10.1186/s12885-019-5510-y.
BMC Cancer. 2019.
PMID: 30940117
Free PMC article.
Clinical Trial.